Triple Negative Breast Cancer News and Research

RSS

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

New metabolic vulnerabilities of subsets of triple-negative breast cancer discovered

Researchers have identified a metabolic enzyme and pathway in some triple-negative breast cancer (TNBC) patients, which they hope could serve as a biomarker to select patients to receive targeted therapy.

16 Nov 2021

Novel study aims to develop personalized treatment for triple-negative breast cancer

Indiana University School of Medicine researcher Bryan P. Schneider, MD, is leading a novel nationwide study to better understand how to treat patients with triple-negative breast cancer based on their own unique genetic data.

8 Nov 2021

Key link between chronic stress and cancer discovered

Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning.

6 Nov 2021

Brooklyn College announces the launch of BCCC-CURE to enhance the lives of cancer patients

Cancer is the second leading cause of death in New York State after heart disease among adults and the second cause of death among children after injuries. And the number of people diagnosed with the disease increases every year.

2 Nov 2021

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center.

2 Nov 2021

UAB researchers show how to identify non-responding tumors and improve immunotherapy response

Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients respond to therapy.

28 Oct 2021

Research group uncovers novel mechanism that regulates breast cancer metastases

A research group at the University of Turku, Finland, has discovered a completely new mechanism that cells use to circulate integrins on the cell surface.

18 Oct 2021

Impact of BRCA1 mRNA expression on survival of patients breast and colorectal cancer

Oncotarget published "Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients" which reported that LMNB2 is a chromatin remodeling protein that also plays a role in eukaryotic cell proliferation by organizing the nuclear membrane during mitosis.

13 Oct 2021

Scientists identify a new method to treat triple-negative breast cancer

A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR's Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less aggressive ('epithelial') to being more aggressive ('mesenchymal'), and vice versa.

7 Oct 2021

Research could lead to new treatment option for breast cancer patients with brain metastases

Breast cancer patients whose cancer spreads to the brain may soon have new treatment options, thanks to research led by CU Cancer Center member Diana Cittelly, PhD.

21 Sep 2021

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.

17 Aug 2021

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

Massachusetts General Hospital researchers have identified for the first time how a highly aggressive form of breast cancer can evade one of the most powerful and effective drugs used to treat it, reporting their findings in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2021

Combining inhibitor drug with immunotherapy agent improves response in cancer patients

Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.

16 Aug 2021

BioCurate’s new “Proof of Concept” funding to help accelerate research into targeted cancer therapies

The first award under BioCurate’s new “Proof of Concept” fund has been granted to the Monash Biomedicine Discovery Institute.

4 Aug 2021

Study finds a significant link between statins and survival rates of triple-negative breast cancer patients

A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.

3 Aug 2021

Hormone-resistant prostate, breast cancers added to clinical trial of experimental DNA therapy

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology's Elenagen, an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer.

3 Aug 2021

New insights on replication-stress sensitivity in breast cancer cells

Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1.

28 Jul 2021

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Jul 2021

Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer

A research team led by Fumito Ito, MD, PhD, FACS, of Roswell Park Comprehensive Cancer Center reports new data on the promise of combining standard treatment for breast cancer with a particular form of cancer immmunotherapy - dendritic-cell (DC) treatment vaccines.

20 Jul 2021